NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced drug ...

Table 1. Percentage of patients decreasing daily levodopa dose by 4–6 weeks after entacapone initiation in Phase III clinical trials as grouped by baseline daily levodopa dose and presence of ...

5 dosage is about 8 hours ... "It is noteworthy that the smooth Levodopa blood profile of LXM.5 is reminiscent of that achieved with pump systems, which place a significant burden on patients ...

reduces 'off' time and allows a reduction in levodopa dose. In early, levodopa-naive PD patients, Stalevo induced more dyskinesia than similar dosages of levodopa/carbidopa, so the regimen tested ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Parkinson's Disease Treatment Market Aging Populations and Advancements in Deep Brain Stimulation, Gene Therapy, and Medications Fuel Marke ...

The backbone of Parkinson’s treatment is levodopa, a compound that is converted to dopamine in the brain to boost levels of this brain chemical that patients lack. The periods when this ...

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

A recent study published in the journal Brain has revealed new insights into the neurological underpinnings of levodopa-induced dyskinesia, a common and debilitating complication of Parkinson’s ...